A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

NCT05491811 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

NCT06785584 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

NCT05186506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

NCT06772610 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

NCT06780839 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

NCT06736561 ·Status: NOT_YET_RECRUITING

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

NCT06779539 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

NCT05178511 ·Status: UNKNOWN ·Phase: PHASE2

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

NCT07235306 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

NCT03804541 ·Status: UNKNOWN ·Phase: PHASE1

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

NCT04146571 ·Status: AVAILABLE

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

NCT06762327 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

NCT03753685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

NCT03647111 ·Status: RECRUITING

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

NCT04415320 ·Status: UNKNOWN ·Phase: PHASE2

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

NCT01500824 ·Status: WITHDRAWN ·Phase: PHASE2

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

NCT05991895 ·Status: RECRUITING

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

NCT03215693 ·Status: UNKNOWN ·Phase: PHASE2

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869 ·Status: RECRUITING

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

NCT03127449 ·Status: TERMINATED ·Phase: NA

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

NCT04762459 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

NCT05117658 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

NCT03906058 ·Status: COMPLETED ·Phase: PHASE2

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

NCT06694129 ·Status: NOT_YET_RECRUITING